ScholarX: KIM, WON SEOG

Detailed Information

KIM, WON SEOG (김원석)

Medicine (Medicine)

Research Area

Tel 02-3410-6548
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Lymphoma:34||Prognosis:24||Diffuse large Bcell lymphoma:17||diffuse large Bcell lymphoma:17||Rituximab:16||EpsteinBarr virus:15||lymphoma:14||Survival:13||Tcell lymphoma:12||Chemotherapy:12||Peripheral Tcell lymphoma:11||prognosis:11||chemotherapy:9||rituximab:9||peripheral Tcell lymphoma:8||Marginal zone:7||Diffuse large B cell lymphoma:7||Burkitt lymphoma:7||Central nervous system:7||Follicular lymphoma:6||s lymphoma:6||Quality of life:6||Bcell lymphoma:6||NonHodgkin lymphoma:6||extranodal NK:5||Biomarker:5||nonHodgkin lymphoma:5||Tcell:5||survival:5||Multiple myeloma:5||NK/Tcell lymphoma:5||Circulating tumor DNA:5||Immunotherapy:5||CHOP:5||Treatment:5||Radiotherapy:5||LMP1:4||B cell lymphoma:4||autologous stem cell transplantation:4||T cell lymphoma:4||Pembrolizumab:4||Intravascular lymphoma:4||Bortezomib:4||Radiation therapy:4||NK:4||Angioimmunoblastic Tcell lymphoma:4||central nervous system:4||brentuximab vedotin:4||overall survival:4||Autologous stem cell transplantation:4||NonHodgkin&apos:4||Mantle cell lymphoma:4||follicular lymphoma:4||diffuse large B cell lymphoma:3||Bcell:3||HL:3||Primary CNS lymphoma:3||infection:3||Exosome:3||Hematopoietic stem cell transplantation:3||angioimmunoblastic Tcell lymphoma:3||autologous hematopoietic stem cell transplantation:3||methotrexate:3||Extranodal NK/Tcell lymphoma:3||Hodgkin disease:3||Hodgkin&apos:3||ABCL:3||Oxaliplatin:3||PET:3||PET/CT:3||prognostic factor:3||prognostic index:3||prophylaxis:3||ECHELON1:3||PI3K/AKT pathway:3||Asia:3||Ibrutinib:3||salvage therapy:3||CD30:3||DLBCL:3||Glioblastoma:3||Therapeutics:3||phase I:2||bone marrow:2||clinical trial:2||Daratumumab:2||EBV:2||CTP10:2||PD1:2||PDL1:2||concurrent chemoradiotherapy:2||MALT lymphoma:2||primary CNS lymphoma:2||IBCL:2||Cyclophosphamide:2||Salvage therapy:2||JAKSTAT pathway:2||Brentuximab vedotin:2||multiple myeloma:2||hepatitis B virus:2||Methotrexate:2||Serum cytokines:2||mosunetuzumab:2||darinaparsin:2||Pharmacokinetics:2||Toxicity:2||Intestine:2||radiotherapy:2||biosimilars:2||ENKTL:2||Primary central nervous system lymphoma:2||refractory:2||Bendamustine:2||Etoposide:2||relapse:2||Radioimmunotherapy:2||doxorubicin:2||relapsed or refractory:2||relapsed/refractory:2||Bone marrow:2||early progression:2||Leukemia:2||elderly:2||Cytomegalovirus:2||marginal zone lymphoma:2||PTCL:2||Gastrointestinal tract:2||Immunohistochemistry:2||Nextgeneration sequencing:2||Extranodal NK/T cell lymphoma:2||everolimus:2||Stem cell transplantation:2||Parathyroid hormonerelated protein:2||young adults:2||mantle cell lymphoma:2||antibodydrug conjugate:2||Gemcitabine:2||RCHOP:2||extranodal NK/Tcell lymphoma:2||Extranodal NK:2||anemia:2||Marginal zone lymphoma:2||Busulfan:2||Diffuse large bcell lymphoma:2||T cell receptor:2||Cancer:2||gastric lymphoma:2||Epidemiology:2||staging:2||stomach:2||Hematopoietic stemcell transplantation:2||Lasparaginase:2||survival outcome:2||Prognostic factors:2||Korea:2||Index:2||Asian:2||Tlymphocytes:2||TCL:2||Mediastinal large Bcell lymphoma:2||international prognostic index:2||treatment:2||hematopoietic stem cell transplantation:2||Phase III:2||Biomarkers:2||Resistance:2||Localized disease:2||oncology:2||cancer:2||pAKT:2||Response:2||Temozolomide:2||Relapse:2||Hypercalcemia:2||cisplatin:2||Liquid biopsy:2||peripheral Tcell lymphomas:2||breast:2||Lymphoplasmacytic lymphoma:2||Lymphoproliferative disorders:2||Frequency:1||Frontal sinus:1||GPS:1||Ganciclovir:1||Gene expression:1||Gene mutation:1||Gene rearrangement:1||Glasgow Prognostic Score:1||Global TCell Lymphoma Consortium:1||Grade:1||Gray zone lymphoma:1||Guidelines:1||Hscore:1||HAT mutation:1||HBsAgnegative:1||HLH2004:1||HOX:1||Hans algorithm:1||Head and neck:1||Hematologic neoplasm:1||Hemophagocytic lymphohistiocytosis:1||Hemophagocytosis:1||Heparin:1||Hepatitis B:1||Hepatitis B virus:1||Hepatosplenic T cell lymphoma:1||Herpesvirus 4, human:1||Histone deacetylase inhibitor:1||Histopathology:1||Hodgkin lymphoma:1||Hodgkin's lymphoma:1||Human herpesvirus 8:1||Human immunodeficiency virus:1||Hyperuricemia:1||Hypoxia:1||I131rituximab:1||ICE:1||ICE/Dexa:1||IL10:1||IL6:1||IRF4:1||IVIG:1||Immune checkpoint inhibitors:1||Immune profiling:1||Immunochemotherapy:1||Immunocompromised host:1||Immunophenotype:1||In situ hybridization:1||Incidence:1||Incubation period:1||Inflammation:1||Interleukin18:1||Intermediate lymphoma:1||International prognostic index:1||Intraocular:1||Intrathecal
chemotherapy:1||Intravascular Bcell lymphoma:1||JACKPOT8:1||JAK/STAT:1||JAK2:1||Japanese subgroup analysis:1||KIR:1||KSH:1||Kidney failure, Acute:1||LAsparaginase:1||LAG3:1||LAG3:1||LILRB1:1||Lacrimal gland:1||Langerhans cell histiocytosis:1||Large Bcell lymphoma:1||LargeB cell:1||Leptomeningeal diseases:1||Leptomeningeal spread:1||Local stage:1||Lung:1||Lymhoma working party:1||Lymph2Cx:1||Lymph2Cx assay:1||Lymphadenopathy:1||Lymphoblastic lymphoma:1||Lymphoid malignancies:1||Lymphoma and Hodgkin disease:1||Lymphoma, follicula:1||M:1||M2 macrophage:1||MALTIPI:1||MAPK:1||MEMOPCR:1||MG4101:1||MHC class Irelated chain A:1||MHC class Irelated chain B:1||MIP1:1||MUM1:1||MYC:1||MYD88 L265P:1||Maintenance:1||Male breast:1||Malignancy:1||Mantlecell:1||Marginal zone B cell lymphoma:1||Marginal zone Bcell lymphoma:1||Massively parallel sequencing:1||Mature NK/Tcell lymphoma:1||Mature Tcell neoplasm:1||Maximum standardized uptake value:1||Medical oncologist:1||Messenger RNA:1||Metaanalysis:1||Methylprednisolone:1||MicroRNA:1||MicroRNA cancer:1||Microarray:1||Middle East respiratory syndrome coronavirus:1||Monomorphic epitheliotropic intestinal Tcell lymphoma:1||Mucosaassociated lymphoid tissues:1||Multicenter:1||Multiple:1||Multiple cranial nerve palsy:1||Multiple myeloma oncogene1:1||Mutations:1||Myeloma:1||N:1||NK cell:1||NK/T:1||NK/Tcell Lymphoma:1||NK/Tcell lymphoma:1||Nasal type:1||Natural Killer Cells:1||Natural killer cells:1||Natural killercell lymphomas:1||Natural killer/T cell lymphoma:1||Neoplasms:1||Nivolumab:1||Nodal peripheral Tcell lymphoma with T follicular helper phenotype:1||NonHodgkin:1||NonHodgkin lymphomaprognosis:1||NonHodgkin’s lymphoma:1||Nontransitional cell carcinoma:1||Novel agents:1||Novel therapy:1||Nutritional assessment:1||Nutural killer cells:1||Ocular adnexal lymphoma:1||Ocular adnexal marginal zone lymphoma:1||Older patients:1||Open label:1||Opioids:1||Orbital lymphoma:1||Ovary:1||Overall survival:1||PAKT:1||PCR:1||PDE5:1||PDL1:1||PEG/PLA:1||PFS outcome:1||PI3K:1||PINK:1||PINK(E):1||PINKB:1||PKD1/PKC mu:1||PKG pathway:1||PLR:1||POD24:1||PTCLNOS:1||Pain:1||Palliative chemotherapy:1||Partial orbital irradiation:1||PatientGenerated Subjective Global Assessment:1||Pediatric Bcell lymphoma:1||Pediatric nodal marginal zone lymphoma:1||Pediatrictype follicular lymphoma:1||Pediatrictype sarcoma:1||Pegfilgrastim:1||Performance status:1||Peripheral:1||Peripheral T cell lymphoma:1||Peripheral Tcell lymphomaNOS:1||Peripheral Tcell lymphomanot otherwise specified:1||Peripheral blood stem cell transplantation:1||Pharmacodynamics:1||Phase 1 clinical trial:1||Phase 2:1||Phase I:1||Phase II:1||Pim1:1||Polatuzumab:1||Positron emission tomography:1||Positron emission tomography/computerized tomography Rituximab:1||Preemptive therapy:1||Prima:1||Primary adrenal lymphoma:1||Primary central nervous system neoplasms:1||Primary effusion lymphoma:1||Primary lymphoma of thyroid:1||Primary nodal EpsteinBarr viruspositive Tcell/NKcell lymphoma:1||Primitive neuroectodermal tumor family:1||Prognosi:1||Prognostic index:1||Prognostic scores:1||Prophylaxis:1||Pseudoprogression:1||Psychosocial wellbeing:1||Pulmonary:1||QuantiFERON monitor:1||R:1||RCVP:1||RAS/MAPK pathway:1||RNA sequencing:1||ROR1:1||Rad:1||Radiation dosage:1||Recurrence:1||Recurrent disease:1||Regimen:1||Relapsed and refractory:1||Relapsed lymphoma:1||Relapsed or refractory:1||Relapsed/refractory:1||Relapsed/refractory extranodal NK/T cell lymphoma:1||Relapsed/refractory large Bcell lymphoma:1||Renal cell carcinoma:1||Renal replacement therapy:1||Restrictive cardiomyopathy:1||Reverse seroconversion:1||Rhabdomyosarcoma:1||Risk factor:1||Risk factors:1||Risk stratification:1||Romidepsin:1||Ruxolitinib:1||S100 protein:1||SARSCoV2:1||SUMO:1||SUMOspecific protease:1||Safety profile:1||Salvage regimen:1||Secondary central nervous system involvement:1||Sequestration:1||Severity of Illness Index:1||Sexual activity:1||Sexual desire:1||Sexual education:1||Sexual knowledge:1||Sexual satisfaction:1||Sildenafil (Viagra):1||Single hit:1||Single switch:1||Solid tumor:1||Soluble PDL1:1||Somatic mutation:1||Splenectomy:1||Stem cell:1||Stomach neoplasms:1||Survival outcome:1||Survivin:1||Survivors:1||Synchronous:1||Sysmex XN analyzer:1||T lymphocytes:1||TCell:1||TCell lymphoma:1||Tfollicular helper cellorigin lymphoma:1||Tlymphoblastic lymphoma:1||TET2:1||TIGIT:1||TNFAIP3 (A20) deletion:1||Therapeutic similarity:1||Thrombocytopenia:1||Thyroid:1||Timetoevent data:1||Transdermal patch:1||Translocation:1||Treatment efficacy:1||Treatment options:1||Treatment pattern:1||Trend:1||Tumor infiltrating lymphocytes:1||Tumor lysis syndrome:1||Tumor mutation burden:1||Tumor suppressor:1||Unspecified:1||Urothelial carcinoma:1||Ursodiol:1||Validation studies:1||Vascular endothelial growth factor:1||Venoocclusive disease:1||Venous thromboembolism:1||Vincristine:1||Vorinostat:1||Waldenstrom macroglobulinemia:1||Waldeyer&apos:1||Western:1||Wholebody irradiation:1||Y90ibritumomab tiuxetan:1||Yttrium90ibritumomab tiuxetan:1||ZNFs:1||[F18] fluorodeoxyglucose:1||aggressive Bcell lymphoma:1||aggressive nonHodgkin lymphoma:1||allogeneic:1||anthracyclinecontaining regimen:1||antiHBcpositive:1||antiviral therapy:1||apheresis:1||autologous HSCT:1||bendamustine:1||beta 2microglobulin:1||bevacizumab:1||biodistribution:1||biomarker:1||bispecific:1||blood level:1||bulky di:1||busulfan:1||cMYC:1||cHL:1||case:1||cell of origin:1||cellfree DNA:1||cellular therapy:1||cemiplimab:1||central nervous system lymphoma:1||cetuximab:1||chemokine:1||chemotherapy resistance:1||chromatin modification:1||chronic GVHD:1||chronic graft versus host disease:1||classical Hodgkin:1||classical Hodgkin lymphoma:1||clinical features:1||clinical grading:1||clinical variables:1||clonogenic assay:1||combination therapy:1||combined modality therapy:1||computed tomography:1||copanlisib:1||critical presentations:1||cyclophosphamide:1||cyclosporine:1||cytarabine:1||cytokine:1||cytomegalovirus:1||cytomorphology:1||deep learning:1||deep vein thrombosis:1||dendritic cell:1||desumoylation:1||diffuse:1||diffuse large Bce:1||drug therapy:1||efficacy:1||elderly patient:1||elderly patients:1||enteropathytype T cell lymphoma:1||epidemiology:1||etoposide:1||exosome:1||expert hematopathologist review:1||extranodal NKTcell lymphoma:1||extranodal NK/T cell lymphoma:1||extranodal NK/Tcell
lymphoma:1||extranodal NK/Tcell lymphoma nasal type:1||fear of cancer recurrence:1||fluorescence in situ hybridization:1||frontline treatment:1||fusion:1||gastric cancer:1||gemcitabine:1||gene expression:1||gene expression profiles:1||glioblastoma:1||golidocitinib:1||graft vs. host disease:1||heavily pretreated:1||hematologic malignancy:1||hematologic neoplasms:1||hematopoietic progenitor cell:1||hemophagocylic:1||hemophagocytic syndrome:1||hemophagocytosis:1||hepatitis:1||hepatitis B reactivation:1||hepcidin:1||highdose chemotherapy:1||highdose methotrexate (HDMTX):1||highgrade lymphoma:1||ibrutinib resistance:1||idiopathic thrombocytopenic purpura:1||ileocecal area:1||image cytometry:1||immune checkpoint:1||immune checkpoint inhibitors:1||immune checkpoints:1||immune evasion:1||immunologic therapy:1||immunological monitoring:1||immunosuppressive treatment:1||immunotherapy:1||incidence:1||indolent Bcell nonHodgkin lymphoma:1||infliximab:1||intensive chemotherapy:1||intestinal:1||intestinal lymphoma:1||intravenous immunoglobulin:1||intravenous immunoglobulins:1||irinotecan:1||isatuximab:1||lactate dehydrogenase:1||large Bcell:1||large Bcell lymphoma:1||large cell:1||large cell lymphoma:1||lenalidomide:1||limitedstage:1||liquid biopsy:1||lymphadenopathy:1||lymphohistiocytosis:1||lymphomaassociated hemophagocytic syndrome:1||lymphopenia:1||lytic induction therapy:1||marginal zone B cell lymphoma:1||marginal zone Bcell lymphoma:1||marginal zone Bcell lymphoma of MALT type:1||metaanalysis:1||metabolic tumor burden:1||metronomic:1||miR1555p:1||miR3405p:1||microarray:1||misdiagnosis:1||molecular biomarker:1||mouse model:1||mucosaassociated lymphoid tissue lymphoma:1||mutation:1||mutational signature:1||myeloma:1||nanoparticle:1||nasal NK/Tcell lymphoma:1||nasal cavities:1||nasal endoscopy:1||nasaltype NK/Tcell ly:1||natural killer group 2 member D:1||neoplasia:1||neutralizing antibody:1||newly diagnosed diffuse large Bcell lymphoma:1||nextgeneration sequencing:1||nextgeneration sequencing (NGS):1||nonhodgkin lymphoma:1||nongastric:1||not otherwise specified:1||ocular:1||paclitaxel:1||paranasal sinus:1||pathogenesis:1||pathology:1||pembrolizumab:1||peripheral blood stem cell transplant:1||pharmacokinetics:1||phase 3:1||phase I/II:1||phase I/II trial:1||phase II trial:1||pitfalls:1||plasma cell neoplasm:1||positron emission tomography:1||postremission therapy:1||precursor cell lymphoblastic leukemialymphoma:1||prednisone:1||primary breast lymphoma:1||primary central nervous system lymphoma:1||primary cutaneous Tcell lymphoma:1||primary organ:1||prog:1||prognostic marker:1||progression:1||progressionfree survival:1||pulmonary embolism:1||radiation therapy:1||randomized clinical trial:1||recurrence:1||recurrent:1||refractory diffuse large Bcell lymphoma:1||regimen group:1||relapsed diffuse large Bcell lymphoma:1||relapsed lymphoma:1||renal cell carcinoma:1||renal impairment:1||renal response:1||risk factors:1||risk stratification:1||rituximab consolidation:1||rituximab resistance:1||s:1||s ring:1||s sarcoma:1||safety:1||salvage chemotherapy:1||salvage treatment:1||secondary CNS involvement:1||secondary maligna:1||sequencing:1||sequential chemoradiotherapy:1||sequential chemotherapy and radiotherapy:1||serum:1||shRNA:1||single cell analysis:1||soluble PDL1:1||soluble interleukin2 receptor:1||soluble transferrin receptor:1||somatic mutation:1||stage I/IINK/Tcell lymphomas:1||surgery:1||survivin:1||targeted deep sequencing:1||tenofovir disoproxil fumarate:1||testis:1||transcriptome:1||transformation:1||transitional cell carcinoma:1||trastuzumab:1||treatment outcomes:1||tumor evolution:1||tumor lysate:1||tumor microenvironment:1||urothelium:1||vascular endothelial growth factor:1||viral load:1||vitamin C:1||vitamin D:1||vorinostat:1||whole blood:1||whole exome:1||wholegenome sequencing:1||β2 microglobulin:1||β2microglobulin:1||펨브롤리주맙:1||131Irituximab:1||호지킨림프종:1||18FFDG:1||18Ffluorodeoxyglucose:1||5azacytidine:1||5fluorouracil:1||A plus CHP:1||AKT:1||ALK:1||ALKpositive:1||ALL:1||AML:1||ANKL:1||ASCT:1||Adjuvant:1||Adjuvant chemotherapy:1||Adjuvant therapy:1||Adult:1||Advanced:1||Advanced stage:1||Adverse events:1||Aggressive T cell lymphoma:1||Aggressive natural killer cell leukemia:1||Albumin:1||Alemtuzumab:1||Alisertib:1||Allogeneic HSCT:1||Allogeneic hematopoietic stem cell transplantation:1||Allogeneic stem cell transplantation:1||Allogeneic transplantation:1||Alloreactivity:1||Amyloidosis:1||Anaplastic large cell lymphoma:1||AnnArbor Stage:1||Antibodydrug conjugate:1||Array comparative genomic hybridization:1||Asians:1||Aspirate:1||Asymptomatic period:1||Autologous hematopoietic stem cell transplantation:1||B cell:1||B cell NHL:1||B cell nonHodgkin lymphoma:1||BCell lymphoma:1||Bcell nonHodgkin's lymphoma:1||BA.5 variant:1||BCL6:1||BCOR:1||BV:1||Bcl2:1||Beta 2microglobulin:1||Bilateral:1||Biology:1||Biosimilar:1||Bispecific antibody:1||Blastic plasmacytoid dendritic cell neoplasm:1||Body cavitybased lymphoma:1||Bronchusassociated lymphoid tissue:1||Bruton's tyrosine kinase inhibitor:1||Burkitt leukemia:1||C11 methionine:1||CAR T:1||CART:1||CCL3:1||CCL4:1||CD19:1||CD20:1||CD274:1||CD28:1||CD3:1||CD34 antigen:1||CD34positive cells:1||CD38:1||CD5:1||CD56:1||CD79B:1||CHOP regimen:1||CISL:1||CLTCALK:1||CNS disease:1||COVID19:1||CSF:1||CT:1||CTP13:1||CTLA4:1||CVAD protocol:1||CXCL10:1||CXCL13:1||Cancer stem cell:1||Cancer stem cells:1||Cancer survivor:1||Cancer survivors:1||Carbonic anhydrase IX:1||Cardiac lymphoma:1||Cell death:1||Cellfree DNA:1||Celloforigin classification:1||Cerebrospinal fluid:1||Chemoresistance:1||Chemokine:1||Chemoradiotherapy:1||Chemotherapeutic dosage:1||Chimeric antigen receptor:1||Chop14:1||Chromatin modification:1||Classification:1||Clinical features:1||Clinical outcomes:1||Clinical research:1||Combined modality therapy:1||Complementary alternative medicine:1||Concomitant chemoradiation:1||Concurrent chemoradiotherapy:1||Conjunctiva:1||Continuous venovenous hemofiltration (CVVH):1||Copanlisib:1||Corticosteroid:1||Cryopreservation:1||CtDNA:1||Cutaneous:1||Cutaneous Tcell lymphoma:1||Cutaneous lymphoma:1||Cyclooxygenase2:1||Cyclophosphamidecontaining regimen:1||Cytarabine:1||Cytokine release syndrome:1||Cytokine toxicity:1||Cytomegalovirus infection:1||DICHOP:1||Desmoplastic small roundcell tumor:1||Dexa:1||Dexamethasone:1||Diffuse:1||Diffuse B cell lymphoma:1||Diffuse large Bcell lym:1||Diffuse large cell lymphomas:1||Digital pathology:1||Distress:1||Donor lymphocyte infusion:1||Double hit:1||Doxorubicin resistance:1||Drug resistance:1||Duodenum:1||Duvelisib:1||EBNA2:1||EBV driven lymphoid malignancies:1||EBV reactivation:1||EBVpositive DLBCL of the elderly:1||EPR effect:1||EbsteinBarr virus:1||Efficacy:1||Egr1:1||Endo:1||Enteropathy:1||Epigenetic mutation:1||Epstein Barr virus:1||EpsteinBarr encoded small nuclear RNA:1||EpsteinBarr virus (EBV):1||EpsteinBarr viruspositive:1||Epsteinbarr virus:1||Epstein–Barr virus:1||Evusheld:1||Ewing sarcoma:1||Ewing&apos:1||Expression:1||Extranodal:1||Extranodal NKTCell:1||Extranodal NK/Tcell lymphoma nasal type:1||Extranodal lymphomas:1||Extranodal natural killer:1||Extranodal natural killer/Tcell lymphoma:1||Extranodal natural killer/Tcell nasal type lymphoma:1||F18 FDG:1||F18FDG:1||FOXO4:1||Fentanyl:1||Fever:1||Fine needle aspiration cytology:1||Flow cytometry:1||Focal lesions:1||Follicular peripheral Tcell lymphoma:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE